Vaxcyte, Inc.

PCVX

US92243G1085

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-06 pm EST			5-day change	1st Jan Change
59.29 ^USD	+1.79%		-3.97%	+28.50%

Feb. 25	Analyst recommendations: IBM, Axon, Caterpillar, Fair Isaac, Gilead…
Feb. 24	Vaxcyte, Inc., Q4 2025 Earnings Call, Feb 24, 2026

Vaxcyte Closes Public Offering of Shares

Published on 02/02/2026 at 05:11 pm EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Vaxcyte, Inc.

Feb. 25	Analyst recommendations: IBM, Axon, Caterpillar, Fair Isaac, Gilead…
Feb. 24	Vaxcyte, Inc., Q4 2025 Earnings Call, Feb 24, 2026
Feb. 24	Vaxcyte enters into sales agreement, may sell shares of common stock of up to $500 million	RE
Feb. 24	Vaxcyte Q4 Loss Widens	MT
Feb. 24	Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Feb. 11	Vaxcyte, Inc. Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines	CI
Feb. 02	Vaxcyte Closes Public Offering of Shares	MT
Jan. 30	Vaxcyte Prices $550 Million Common Stock Offering	MT
Jan. 29	Vaxcyte Launches $500 Million Public Offering	MT
Jan. 22	Vaxcyte advances adult and infant programs for Vax-31, a potential best-in-class, next-generation pneumococcal conjugate vaccine	RE
Jan. 22	Vaxcyte, Inc. Advances Adult and Infant Programs for VAX-31, a Potential Best-In-Class, Next-Generation Pneumococcal Conjugate Vaccine	CI
Dec. 08	Vaxcyte Doses First Patients in Phase 3 Trial of VAX-31 in Invasive Pneumococcal Disease, Pneumonia	MT
Dec. 08	Vaxcyte says topline results from OPUS trial expected in Q4 2026	RE
Dec. 08	Vaxcyte, Inc. Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults	CI
Dec. 01	Vaxcyte, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-19-2025 02:30 PM

Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâ€™s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.

Employees

507

Sector

Biotechnology & Medical Research

More about the company